Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded to “Strong-Buy” at Wolfe Research

Wolfe Research upgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.

CNTA has been the topic of a number of other reports. Stephens began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price on the stock. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Chardan Capital restated a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Truist Financial upped their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average price target of $38.64.

Centessa Pharmaceuticals Trading Up 4.0%

NASDAQ CNTA opened at $26.52 on Monday. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $30.58. The company’s 50-day moving average price is $24.25 and its 200-day moving average price is $23.47. The stock has a market cap of $3.87 billion, a PE ratio of -14.49 and a beta of 1.56. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36.

Insiders Place Their Bets

In related news, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 49,961 shares of company stock worth $1,304,878 over the last quarter. Company insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Millennium Management LLC raised its stake in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after acquiring an additional 210,737 shares in the last quarter. Jane Street Group LLC purchased a new position in Centessa Pharmaceuticals in the first quarter worth $2,176,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Centessa Pharmaceuticals during the second quarter worth $613,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at $218,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 44.7% during the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after purchasing an additional 26,994 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.